Aromatase inhibitor shows promise for breast cancer patients
30th Dec 2005, 08:16 GMT
Filed under: Breast Cancer, Drug Women with hormone-sensitive early breast cancer are getting benefits from the drug Novartis's Femara. The Swiss drug maker presented data at the 28th annual San Antonio Breast Cancer Symposium in Texas revealing that the aromatase inhibitor showed a benefit in starting therapy up to five years after the end of standard tamoxifen treatment. In a press relaes Novartis claimed, "Postmenopausal women who switched from placebo to Femara experienced a 69-percent reduction in the risk that their breast cancer would return." Read | Permalink | Email this | Linking Blogs | Comments
Aromatase inhibitor shows promise for breast cancer patients related news:
- FDA Expands Femara Indication to Early Breast Cancer — MedPage Today.com Latest Headlines
- One day radiation may become an option for breast cancer patients — EurekAlert! - Breaking News
- New Breast Cancer Treatment Guidelines Published (American Cancer Society) — Yahoo! Health: Breast Cancer News
- Study Sees Benefit in High-Dose Chemotherapy for Breast Cancer (American Cancer Society) — Yahoo! Health: Breast Cancer News
- Too Many Cancer Patients Continue to Smoke (HealthDay) — Yahoo! Health: Lung Cancer News
- New breast cancer drug 21 percent as effective as tamoxifen in preventing relapse — The Earth Times Online Newspaper
- SIGN breast cancer guidleines promote radiotherapy and palliative care benefits — OnMedica Latest News
- Art Therapy Can Reduce Pain and Anxiety in Cancer Patients — Kansas City infoZine Arts Headlines
- Breast cancer wonder drug hailed — Scotsman.com News - Cancer research
- Wonderfully inspiring survivors — The Cancer Blog